
Agilent Technologies A
$ 111.3
-3.12%
Quarterly report 2025-Q4
added 03-03-2026
Agilent Technologies EV - Enterprise Value 2011-2026 | A
Annual EV - Enterprise Value Agilent Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 45.8 B | 39.3 B | 28.7 B | 24.9 B | 23.2 B | 15.6 B | 15.2 B | 16.7 B | 15.8 B | 12.5 B | 10.5 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.8 B | 10.5 B | 22.6 B |
EV - Enterprise Value of other stocks in the Diagnostics research industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-19.1 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
1.64 B | - | -17.87 % | $ 25.9 M | ||
|
Biocept
BIOC
|
15 M | - | -13.05 % | $ 7.29 M | ||
|
Aspira Women's Health
AWH
|
10.6 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
92.6 M | - | -61.36 % | $ 2.46 M | ||
|
Koninklijke Philips N.V.
PHG
|
13.2 B | $ 25.58 | -5.68 % | $ 20 B | ||
|
CareDx, Inc
CDNA
|
1.04 B | $ 20.8 | -5.07 % | $ 1.11 B | ||
|
Chembio Diagnostics
CEMI
|
39.2 M | - | 0.22 % | $ 16.8 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
26.2 M | - | - | $ 562 M | ||
|
Check-Cap Ltd.
CHEK
|
2.55 M | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
-1.92 M | $ 1.53 | -6.13 % | $ 2.04 M | ||
|
Castle Biosciences
CSTL
|
665 M | $ 24.24 | -1.86 % | $ 673 M | ||
|
DermTech
DMTK
|
70.4 M | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
-2.77 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
6.64 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
9.21 B | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
251 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
11.4 B | $ 163.84 | -1.77 % | $ 8.12 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
5.02 B | - | - | $ 10.7 B | ||
|
Enzo Biochem
ENZ
|
-22.7 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
22 B | - | - | $ 19.8 B | ||
|
Guardant Health
GH
|
15.2 B | $ 83.41 | 0.35 % | $ 10.5 B | ||
|
Fulgent Genetics
FLGT
|
502 M | $ 14.8 | -3.27 % | $ 447 M | ||
|
Heska Corporation
HSKA
|
851 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
3.16 M | - | -20.0 % | $ 1.06 M | ||
|
Interpace Biosciences
IDXG
|
16.3 M | $ 1.99 | 2.9 % | $ 8.8 M | ||
|
Illumina
ILMN
|
15.3 B | $ 120.37 | -5.16 % | $ 19.1 B | ||
|
QIAGEN N.V.
QGEN
|
11.3 B | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
6.63 M | $ 2.16 | -1.22 % | $ 4.96 M | ||
|
Lantheus Holdings
LNTH
|
5.9 B | $ 81.17 | -2.85 % | $ 5.48 B | ||
|
ICON Public Limited Company
ICLR
|
26.4 B | $ 116.17 | 13.35 % | $ 9.58 B | ||
|
Laboratory Corporation of America Holdings
LH
|
33.1 B | $ 257.14 | -0.94 % | $ 21.4 B | ||
|
Medpace Holdings
MEDP
|
14 B | $ 413.59 | 0.93 % | $ 11.9 B | ||
|
Celcuity
CELC
|
5.57 B | $ 119.0 | -0.89 % | $ 5.56 B | ||
|
Motus GI Holdings
MOTS
|
568 K | - | -34.28 % | $ 263 K | ||
|
NeoGenomics
NEO
|
1.85 B | $ 8.96 | -0.67 % | $ 1.15 B | ||
|
Neogen Corporation
NEOG
|
2.26 B | $ 9.01 | -3.53 % | $ 1.95 B | ||
|
National Research Corporation
NRC
|
432 M | $ 16.54 | -1.78 % | $ 370 M | ||
|
Invitae Corporation
NVTA
|
2.11 B | - | - | $ 21.2 M | ||
|
Myriad Genetics
MYGN
|
598 M | $ 4.68 | -3.31 % | $ 433 M | ||
|
OpGen
OPGN
|
10.3 M | - | -16.95 % | $ 1.54 M | ||
|
Natera
NTRA
|
5.53 B | $ 194.75 | -2.71 % | $ 19.2 B | ||
|
Quest Diagnostics Incorporated
DGX
|
22.9 B | $ 189.32 | -2.94 % | $ 21 B | ||
|
Burning Rock Biotech Limited
BNR
|
433 M | $ 16.24 | -2.46 % | $ 175 M | ||
|
Organovo Holdings
ONVO
|
-4.05 M | - | -2.3 % | $ 19.4 M | ||
|
PerkinElmer
PKI
|
4 B | - | -0.91 % | $ 14.7 B | ||
|
Personalis
PSNL
|
229 M | $ 5.04 | -8.36 % | $ 299 M | ||
|
Precipio
PRPO
|
42.5 M | $ 29.94 | -5.73 % | $ 48.1 M | ||
|
Exagen
XGN
|
78.4 M | $ 2.76 | 1.1 % | $ 59.5 M |